Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial

Bibliographic Details
Main Authors: Becker, F, Dakin, H, Reed, S, Li, Y, Leal, J, Gustavson, S, Kartman, B, Wittbrodt, E, Gray, A, Hernandez, A, Holman, R
Format: Conference item
Published: Springer Verlag 2018
_version_ 1797065644071452672
author Becker, F
Dakin, H
Reed, S
Li, Y
Leal, J
Gustavson, S
Kartman, B
Wittbrodt, E
Gray, A
Hernandez, A
Holman, R
author_facet Becker, F
Dakin, H
Reed, S
Li, Y
Leal, J
Gustavson, S
Kartman, B
Wittbrodt, E
Gray, A
Hernandez, A
Holman, R
author_sort Becker, F
collection OXFORD
description
first_indexed 2024-03-06T21:31:31Z
format Conference item
id oxford-uuid:44d49889-da85-47f0-8620-e3cbf3f9a048
institution University of Oxford
last_indexed 2024-03-06T21:31:31Z
publishDate 2018
publisher Springer Verlag
record_format dspace
spelling oxford-uuid:44d49889-da85-47f0-8620-e3cbf3f9a0482022-03-26T15:04:06ZLifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trialConference itemhttp://purl.org/coar/resource_type/c_5794uuid:44d49889-da85-47f0-8620-e3cbf3f9a048Symplectic Elements at OxfordSpringer Verlag2018Becker, FDakin, HReed, SLi, YLeal, JGustavson, SKartman, BWittbrodt, EGray, AHernandez, AHolman, R
spellingShingle Becker, F
Dakin, H
Reed, S
Li, Y
Leal, J
Gustavson, S
Kartman, B
Wittbrodt, E
Gray, A
Hernandez, A
Holman, R
Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
title Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
title_full Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
title_fullStr Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
title_full_unstemmed Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
title_short Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
title_sort lifetime cost effectiveness simulation of exenatide once weekly in type 2 diabetes evidence from the exscel trial
work_keys_str_mv AT beckerf lifetimecosteffectivenesssimulationofexenatideonceweeklyintype2diabetesevidencefromtheexsceltrial
AT dakinh lifetimecosteffectivenesssimulationofexenatideonceweeklyintype2diabetesevidencefromtheexsceltrial
AT reeds lifetimecosteffectivenesssimulationofexenatideonceweeklyintype2diabetesevidencefromtheexsceltrial
AT liy lifetimecosteffectivenesssimulationofexenatideonceweeklyintype2diabetesevidencefromtheexsceltrial
AT lealj lifetimecosteffectivenesssimulationofexenatideonceweeklyintype2diabetesevidencefromtheexsceltrial
AT gustavsons lifetimecosteffectivenesssimulationofexenatideonceweeklyintype2diabetesevidencefromtheexsceltrial
AT kartmanb lifetimecosteffectivenesssimulationofexenatideonceweeklyintype2diabetesevidencefromtheexsceltrial
AT wittbrodte lifetimecosteffectivenesssimulationofexenatideonceweeklyintype2diabetesevidencefromtheexsceltrial
AT graya lifetimecosteffectivenesssimulationofexenatideonceweeklyintype2diabetesevidencefromtheexsceltrial
AT hernandeza lifetimecosteffectivenesssimulationofexenatideonceweeklyintype2diabetesevidencefromtheexsceltrial
AT holmanr lifetimecosteffectivenesssimulationofexenatideonceweeklyintype2diabetesevidencefromtheexsceltrial